Safety of Nonsteroidal Anti‐Inflammatory Drug Use in Traumatic Brain Injury
Authors:
- Jennifer BeaversJBJennifer Beavers
- Mary Katherine Cella ShultzMSMary Katherine Cella Shultz
- Cara LwinCLCara Lwin
- Dandan LiuDLDandan Liu
- Silky ChotaiSCSilky Chotai
- Andrew J. MedveczAMAndrew J. Medvecz
- Robel BeyeneRBRobel Beyene
- Michael C. SmithMSMichael C. Smith
- Bradley M. DennisBDBradley M. Dennis
- Susan HamblinSHSusan Hamblin
Open Access
- 11 September 2026
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (10)
Abstract
Background: Use of nonsteroidal anti‐inflammatory drugs (NSAIDs) after a traumatic brain injury (TBI) is controversial due to potential worsening of an intracranial hemorrhage (ICH). This study evaluated if NSAID use within 14 days of TBI was associated with a clinically significant progression of intracranial bleed (PIB). Methods: A retrospective, propensity score‐weighted study was conducted in adult patients with a TBI admitted to an American College of Surgeons Certified Level I Trauma Center. The NSAID group included patients who received at least one dose of an NSAID within 14 days of injury while admitted. The control group included patients who did not receive NSAIDs. The primary end point was incidence of a clinically significant PIB (decrease in the Glasgow Coma Score (GCS) > 2 and an increased or new ICH). Secondary outcomes included need for additional neurosurgical intervention and PIB on imaging regardless of GCS change. Results: 978 patients were included: 284 in the NSAID group and 694 in the control group. Most patients had an Abbreviated Injury Score head > 2 (88%) and a subdural hematoma (57%). Fifty‐two percent of patients had a mixed bleed. A clinically significant PIB occurred in 0.35% in the NSAID group and 1.2% in the control group (Hazards Ratio 0.1, 95% Confidence Interval 0.01–0.82, p = 0.032). There was no difference in additional neurosurgical operations or PIB regardless of GCS change. In the NSAID group, there was no significant difference in time from admission to NSAID administration between patients who experienced a PIB and those who did not have a PIB (1.9 days vs. 4.7 days, respectively, p = 0.06). Conclusion: In this single‐center, retrospective, propensity score‐weighted study, NSAIDs were not associated with an increased risk of clinically significant PIB in patients with acute TBI when administered within 14 days of injury. NSAIDs appear safe in the acute phase post‐TBI. Prospective studies are needed to validate our results.Keywords
This publication has 11 references indexed in Scilit:
- Hemorrhage Progression in Traumatic Brain Injury Occurs Early and is Not Increased by Administration of NaproxenSSRN Electronic Journal, 2023
- Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-AnalysisNeurotrauma Reports, 2022
- Nonsteroidal anti-inflammatory drug use and concussions in adolescent athletes: incidence, severity, and recoveryJournal of neurosurgery. Pediatrics, 2021
- Antithrombotic agents and traumatic brain injury in the elderly population: hemorrhage patterns and outcomesJournal of Neurosurgery, 2020
- Use of anti-platelet agents after traumatic intracranial hemorrhageClinical Neurology and Neurosurgery, 2016
- Clinical outcomes in patients on preinjury ibuprofen with traumatic brain injuryThe American Journal of Surgery, 2015
- The natural history of brain contusion: an analysis of radiological and clinical progressionJournal of Neurosurgery, 2010
- Effects of Antiplatelet Agents on Outcomes for Elderly Patients With Traumatic Intracranial Hemorrhage2005
- Progressive hemorrhage after head trauma: predictors and consequences of the evolving injuryJournal of Neurosurgery, 2002
- The ABCs of Measuring Intracerebral Hemorrhage VolumesStroke, 1996